Patents by Inventor Paul Gerard Bulger

Paul Gerard Bulger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Regioselective N-2 arylation of indazoles
    Patent number: 10435386
    Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: October 8, 2019
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Cheol K. Chung, Mark E. Scott, Paul Gerard Bulger, Kevin Michael Belyk, John Limanto, Guy R. Humphrey
  • Biocatalytic transamination process
    Patent number: 10407702
    Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can be used to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors which may be useful for the treatment of cancer.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: September 10, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Paul Gerard Bulger, Birgit Kosjek, Nelo Rivera
  • Biocatalytic Transamination Process
    Publication number: 20170335359
    Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can be used to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors which may be useful for the treatment of cancer.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 23, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul Gerard Bulger, Birgit Kosjek, Nelo Rivera
  • Biocatalytic transamination process
    Patent number: 9738915
    Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can be used to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors which may be useful for the treatment of cancer.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: August 22, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Paul Gerard Bulger, Birgit Kosjek, Nelo Rivera
  • REGIOSELECTIVE N-2 ARYLATION OF INDAZOLES
    Publication number: 20170137403
    Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.
    Type: Application
    Filed: January 30, 2017
    Publication date: May 18, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Cheol K. Chung, Mark E. Scott, Paul Gerard Bulger, Kevin Michael Belyk, John Limanto, Guy R. Humphrey
  • Regioselective N-2 arylation of indazoles
    Patent number: 9580407
    Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: February 28, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cheol K. Chung, Mark E. Scott, Paul Gerard Bulger, Kevin Michael Belyk, John Limanto, Guy R. Humphrey
  • Biocatalytic Transamination Process
    Publication number: 20160040201
    Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: employing dynamic kinetic resolution (DKR). The DKR process involves an enzymatic enantioselective amination reaction catalyzed by transaminases. The process can be used to manufacture key intermediates in the preparation of poly (ADP-ribose) polymerase (PARP) inhibitors which may be useful for the treatment of cancer.
    Type: Application
    Filed: December 3, 2013
    Publication date: February 11, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul Gerard Bulger, Birgit Kosjek, Nelo Rivera
  • Regioselective N-2 Arylation of Indazoles
    Publication number: 20150299167
    Abstract: A novel process is provided for the efficient preparation of an asymmetric compound of structural formula I: comprising a copper-catalyzed, carbon-nitrogen cross-coupling step. The process described as part of the present invention can be used to manufacture poly (ADP-ribose) polymerase (PARP) inhibitors, which may be useful for the treatment of cancer. In particular, the present invention describes a process for the manufacture of the PARP inhibitor, 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide.
    Type: Application
    Filed: December 3, 2013
    Publication date: October 22, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Cheol K. Chung, Mark E. Scott, Paul Gerard Bulger, Kevin Michael Belyk, John Limanto, Guy R. Humphrey